In skeletal muscle cells, SELENOW was shown to reduce the binding of 14-3-3 to a transcriptional co-activator with PDZ-binding motif (TAZ) (23), allowing TAZ translocation to the nucleus and subsequent activation of muscle cell differentiation genes (24)
10.1038/nrm3801 39 HongS.HuhJ
doi: 10.1056/NEJMoa073443 109 de VriesLShtaifBPhillipMGat-YablonskiG
We demonstrated that in senescent vascular endothelial cells, FOXO4-DRI effectively disrupts the FOXO4-p53 interaction
GH inhibits 11-hydroxysteroid dehydrogenase type 1 (11HSD-1), a microsomal enzyme required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue
Cagrilintidesemaglutide in adults with overweight or obesity and type 2 diabetes (Redefine 2 trial) Summary: This Phase 3a, double-blind, randomized, placebo-controlled trial investigated the efficacy and safety of once-weekly subcutaneous cagrilintidesemaglutide (2.4 mg each) in adults with a BMI of 27 or more and type 2 diabetes
